Phenominer Database Results (52 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Clinical Measurement Notes Record ID Study ID
SD ejection fraction artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. cardiac output trait male 0 days 6 65.0 % 3.0 7.35 HP Sonos 5500 echo ultrasound 1.0 ACF 360 min 98878 2160
SD heart left ventricle end-diastolic diameter sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 7.3 mm 0.3 0.73 HP Sonos 5500 echo ultrasound 1.0 sham ACF 720 min 98845 2160
SD heart left ventricle end-systolic diameter sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-systolic diameter male 0 days 6 3.8 mm 0.2 0.49 HP Sonos 5500 echo ultrasound 1.0 sham ACF 720 min 98853 2160
SD heart left ventricle end-systolic diameter artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-systolic diameter male 0 days 6 4.1 mm 0.5 1.22 HP Sonos 5500 echo ultrasound 1.0 ACF 5 days 98856 2160
SD heart left ventricle end-diastolic posterior wall thickness sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle posterior wall thickness male 0 days 6 1.6 mm 0.2 0.49 HP Sonos 5500 echo ultrasound 1.0 sham ACF 720 min 98861 2160
SD heart rate artificial aortocaval fistula (for 2 days) then metoprolol succinate (100 mg/kg/d) (for 2 days) then xylazine (10 mg/kg) and ketamine (80 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart pumping trait male 0 days 6 378.0 beats/min 10.0 24.49 HP Sonos 5500 echo ultrasound 1.0 ACF 2 days 98803 2160
SD heart left ventricle end-diastolic diameter to posterior wall thickness ratio sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 4.6 null 0.2 0.49 HP Sonos 5500 echo ultrasound 1.0 sham ACF 2 days heart left ventricle end-diastolic diameter to posterior wall thickness ratio 98871 2160
SD heart left ventricle end-diastolic diameter to posterior wall thickness ratio sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 4.4 null 0.4 0.98 HP Sonos 5500 echo ultrasound 1.0 sham ACF 5 days heart left ventricle end-diastolic diameter to posterior wall thickness ratio 98873 2160
SD ejection fraction sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. cardiac output trait male 0 days 6 63.0 % 3.0 7.35 HP Sonos 5500 echo ultrasound 1.0 sham ACF 720 min 98881 2160
SD heart rate artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart pumping trait male 0 days 6 419.0 beats/min 21.0 51.44 HP Sonos 5500 echo ultrasound 1.0 ACF 720 min 98795 2160
SD heart rate sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart pumping trait male 0 days 6 380.0 beats/min 10.0 24.49 HP Sonos 5500 echo ultrasound 1.0 sham ACF 2 days 98802 2160
SD heart left ventricle end-diastolic diameter to posterior wall thickness ratio artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 5.2 null 0.2 0.49 HP Sonos 5500 echo ultrasound 1.0 ACF 720 min heart left ventricle end-diastolic diameter to posterior wall thickness ratio 98868 2160
SD heart left ventricle end-diastolic diameter to posterior wall thickness ratio artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 5.3 null 0.2 0.49 HP Sonos 5500 echo ultrasound 1.0 ACF 5 days heart left ventricle end-diastolic diameter to posterior wall thickness ratio 98872 2160
SD ejection fraction sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. cardiac output trait male 0 days 6 65.0 % 3.0 7.35 HP Sonos 5500 echo ultrasound 1.0 sham ACF 2 days 98883 2160
SD ejection fraction artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. cardiac output trait male 0 days 6 75.0 % 3.0 7.35 HP Sonos 5500 echo ultrasound 1.0 ACF 5 days 98884 2160
SD heart left ventricle end-diastolic diameter sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 7.1 mm 0.2 0.49 HP Sonos 5500 echo ultrasound 1.0 sham ACF 2 days 98847 2160
SD heart left ventricle end-diastolic posterior wall thickness artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle posterior wall thickness male 0 days 6 1.4 mm 0.2 0.49 HP Sonos 5500 echo ultrasound 1.0 ACF 720 min 98860 2160
SD heart rate sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart pumping trait male 0 days 6 385.0 beats/min 11.0 26.94 HP Sonos 5500 echo ultrasound 1.0 sham ACF 360 min 98794 2160
SD heart rate artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart pumping trait male 0 days 6 420.0 beats/min 14.0 34.29 HP Sonos 5500 echo ultrasound 1.0 ACF 2 days 98801 2160
SD heart left ventricle end-diastolic diameter to posterior wall thickness ratio sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 4.4 null 0.4 0.98 HP Sonos 5500 echo ultrasound 1.0 sham ACF 360 min heart left ventricle end-diastolic diameter to posterior wall thickness ratio 98867 2160
SD heart rate artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart pumping trait male 0 days 6 405.0 beats/min 10.0 24.49 HP Sonos 5500 echo ultrasound 1.0 ACF 2 days 98797 2160
SD heart rate artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart pumping trait male 0 days 6 395.0 beats/min 5.0 12.25 HP Sonos 5500 echo ultrasound 1.0 ACF 5 days 98799 2160
SD heart rate sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart pumping trait male 0 days 6 365.0 beats/min 15.0 36.74 HP Sonos 5500 echo ultrasound 1.0 sham ACF 5 days 98800 2160
SD ejection fraction artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. cardiac output trait male 0 days 6 66.0 % 4.0 9.8 HP Sonos 5500 echo ultrasound 1.0 ACF 720 min 98880 2160
SD heart left ventricle end-diastolic diameter artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 8.1 mm 0.2 0.49 HP Sonos 5500 echo ultrasound 1.0 ACF 2 days 98846 2160
SD heart left ventricle end-diastolic diameter sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 7.1 mm 0.2 0.49 HP Sonos 5500 echo ultrasound 1.0 sham ACF 5 days 98849 2160
SD heart left ventricle end-systolic diameter sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-systolic diameter male 0 days 6 4.2 mm 0.3 0.73 HP Sonos 5500 echo ultrasound 1.0 sham ACF 360 min 98851 2160
SD heart left ventricle end-systolic diameter artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-systolic diameter male 0 days 6 4.1 mm 0.3 0.73 HP Sonos 5500 echo ultrasound 1.0 ACF 2 days 98854 2160
SD heart left ventricle end-systolic diameter sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-systolic diameter male 0 days 6 4.0 mm 0.2 0.49 HP Sonos 5500 echo ultrasound 1.0 sham ACF 2 days 98855 2160
SD heart rate sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart pumping trait male 0 days 6 395.0 beats/min 11.0 26.94 HP Sonos 5500 echo ultrasound 1.0 sham ACF 720 min 98796 2160
SD heart rate sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart pumping trait male 0 days 6 389.0 beats/min 9.0 22.05 HP Sonos 5500 echo ultrasound 1.0 sham ACF 2 days 98798 2160
SD heart rate artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart pumping trait male 0 days 6 436.0 beats/min 18.0 44.09 HP Sonos 5500 echo ultrasound 1.0 ACF 360 min 98793 2160
SD ejection fraction sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. cardiac output trait male 0 days 6 65.0 % 2.0 4.9 HP Sonos 5500 echo ultrasound 1.0 sham ACF 360 min 98879 2160
SD ejection fraction artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. cardiac output trait male 0 days 6 75.0 % 3.0 7.35 HP Sonos 5500 echo ultrasound 1.0 ACF 2 days 98882 2160
SD ejection fraction sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. cardiac output trait male 0 days 6 64.0 % 3.0 7.35 HP Sonos 5500 echo ultrasound 1.0 sham ACF 5 days 98885 2160
SD heart left ventricle end-diastolic diameter artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 7.4 mm 0.3 0.73 HP Sonos 5500 echo ultrasound 1.0 ACF 360 min 98842 2160
SD heart left ventricle end-diastolic diameter sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 7.2 mm 0.3 0.73 HP Sonos 5500 echo ultrasound 1.0 sham ACF 360 min 98843 2160
SD heart left ventricle end-systolic diameter artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-systolic diameter male 0 days 6 3.8 mm 0.4 0.98 HP Sonos 5500 echo ultrasound 1.0 ACF 360 min 98850 2160
SD heart left ventricle end-systolic diameter sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-systolic diameter male 0 days 6 3.9 mm 0.3 0.73 HP Sonos 5500 echo ultrasound 1.0 sham ACF 5 days 98857 2160
SD heart left ventricle end-diastolic posterior wall thickness sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle posterior wall thickness male 0 days 6 1.6 mm 0.2 0.49 HP Sonos 5500 echo ultrasound 1.0 sham ACF 360 min 98859 2160
SD heart left ventricle end-diastolic posterior wall thickness artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle posterior wall thickness male 0 days 6 1.3 mm 0.1 0.24 HP Sonos 5500 echo ultrasound 1.0 ACF 2 days 98862 2160
SD heart left ventricle end-diastolic diameter to posterior wall thickness ratio artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 5.1 null 0.5 1.22 HP Sonos 5500 echo ultrasound 1.0 ACF 360 min heart left ventricle end-diastolic diameter to posterior wall thickness ratio 98866 2160
SD heart left ventricle end-diastolic diameter to posterior wall thickness ratio artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 5.9 null 0.3 0.73 HP Sonos 5500 echo ultrasound 1.0 ACF 2 days heart left ventricle end-diastolic diameter to posterior wall thickness ratio 98870 2160
SD heart left ventricle end-diastolic diameter artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 7.8 mm 0.4 0.98 HP Sonos 5500 echo ultrasound 1.0 ACF 720 min 98844 2160
SD heart left ventricle end-diastolic diameter artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 7.9 mm 0.2 0.49 HP Sonos 5500 echo ultrasound 1.0 ACF 5 days 98848 2160
SD heart left ventricle end-systolic diameter artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-systolic diameter male 0 days 6 4.1 mm 0.4 0.98 HP Sonos 5500 echo ultrasound 1.0 ACF 720 min 98852 2160
SD heart left ventricle end-diastolic posterior wall thickness artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle posterior wall thickness male 0 days 6 1.4 mm 0.2 0.49 HP Sonos 5500 echo ultrasound 1.0 ACF 360 min 98858 2160
SD heart left ventricle end-diastolic posterior wall thickness sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle posterior wall thickness male 0 days 6 1.6 mm 0.2 0.49 HP Sonos 5500 echo ultrasound 1.0 sham ACF 2 days 98863 2160
SD heart left ventricle end-diastolic posterior wall thickness sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle posterior wall thickness male 0 days 6 1.6 mm 0.1 0.24 HP Sonos 5500 echo ultrasound 1.0 sham ACF 5 days 98865 2160
SD heart rate sham surgical control condition (for 2 days) then metoprolol succinate (100 mg/kg/d) (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart pumping trait male 0 days 6 365.0 beats/min 7.0 17.15 HP Sonos 5500 echo ultrasound 1.0 sham ACF 2 days 98805 2160
SD heart left ventricle end-diastolic diameter to posterior wall thickness ratio sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle end-diastolic diameter male 0 days 6 4.5 null 0.5 1.22 HP Sonos 5500 echo ultrasound 1.0 sham ACF 720 min heart left ventricle end-diastolic diameter to posterior wall thickness ratio 98869 2160
SD heart left ventricle end-diastolic posterior wall thickness artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15. heart left ventricle posterior wall thickness male 0 days 6 1.5 mm 0.3 0.73 HP Sonos 5500 echo ultrasound 1.0 ACF 5 days 98864 2160